Arrowhead Eager To Take On ‘Straightforward’ NASH Approach Abandoned By J&J

15 Feb 2023

J&J pipeline review results in return of PNPLA3-targeted NASH candidate optioned under 2018 alliance, but the fate of a hepatitis B candidate included in that deal is undetermined so far.

Arrowheads — Arrowhead will take over NASH candidate once licensed to J&J • Source: Shutterstock

Possibly putting the best face forward on a deep-pocketed partner leaving a collaboration, Arrowhead Pharmaceuticals, Inc. CEO Christopher Anzalone told Scrip his company is excited to reacquire non-alcoholic steatohepatitis (NASH) candidate ARO-PNPLA3/JNJ-75220795 from Johnson & Johnson, saying on 15 February the Phase I candidate could offer a clear shot on goal in a well-defined NASH subpopulation.

J&J is undertaking a strategic review of its pipeline and notified Arrowhead within the past few days that it will...